Market reactionShares fell 18% on Nov 5.
Traws Pharma is a clinical-stage company developing oral antivirals, led by tivoxavir marboxil (TXM) for preventing influenza and ratutrelvir for COVID-19; none of its products is approved.
Traws' case rests on tivoxavir marboxil (TXM), an oral once-monthly influenza preventive, and both of its regulatory paths are blocked. FDA has the U.S. IND on clinical hold over mutagenicity data, and in June the UK's MHRA deferred the planned human challenge study. Traws has not announced the updated toxicology package it planned to resubmit at the end of the third quarter. Cash was $5.0 million at June 30, expected to last into the first quarter of 2027, with substantial doubt about continuing as a going concern.
Thesis checklist
2 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: The MHRA accepts the updated toxicology package
Does the MHRA accept Traws' updated toxicology package and let the challenge study proceed?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Traws' influenza drug TXM is on clinical hold in the U.S. and awaits an updated toxicology resubmission to the UK regulator, which deferred its challenge study in June; cash of $5.0 million at June 30 is expected to last into the first quarter of 2027
TXM's influenza prophylaxis thesis hinges on whether MHRA concerns can be resolved and a human challenge trial delivered before Q1 2027 runway expires
MHRA negative review defers TXM Phase 2a Challenge Trial
Tivoxavir marboxil's June 2026 influenza challenge trial is the binary that determines whether a once-monthly oral prophylactic can advance to registration studies
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Infectious diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
2 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.